Shares of Centogene NV CNTG, -5.04% gained 7% premarket on Friday after the company announced data confirming the utility of its proprietary biomarker lyso-Gb1 in indicating the severity of Gaucher disease, a rare inherited disorder that affects the body’s ability to break down a certain type of fat. The study results also indicate that lyso-Gb1 could help predict the clinical course of patients and personalize care for the disease, Centogene said in a release. “The progressive increase in lyso-Gb1 levels in untreated Gaucher patients suggests that these patients could benefit from treatment, such as enzyme replacement therapy,” Dr. Tobias Bottcher, Centogene’s director of clinical neurogenetics, said in a statement. Centogene shares have gained 28% in the year to date, while the S&P 500 SPX, +0.18% has gained 17.4%.
This article was originally published by Marketwatch.com. Read the original article here.
